Talis Biomedical Corporation (TLIS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Talis Biomedical Corporation (TLIS) trades at $2.84 with AI Score 51/100 (Grade B). Talis Biomedical Corporation specializes in molecular diagnostics, developing the Talis One system for point-of-care infectious disease testing. Market cap: $5.18M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for TLIS: TLIS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TLIS against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TLIS: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Talis Biomedical Corporation (TLIS) Healthcare & Pipeline Overview
Talis Biomedical Corporation is a molecular diagnostics firm developing the Talis One system for point-of-care infectious disease testing. Headquartered in Menlo Park, US, it focuses on rapid detection of pathogens like SARS-CoV-2, with a pipeline expanding into respiratory, women's health, and sexually transmitted infections, addressing limitations in current diagnostic technologies.
What Is the Investment Thesis for TLIS?
Talis Biomedical Corporation is positioned in the molecular diagnostics market with its proprietary Talis One system, designed for rapid point-of-care infectious disease testing. The company's current offering, the Talis One COVID-19 Test System, demonstrates its capability in developing and deploying diagnostic solutions. A key value driver lies in its expansive pipeline, which includes assay kits for respiratory infections, women's health, and sexually transmitted infections, indicating a strategy for diversified revenue streams beyond COVID-19. The company exhibits a strong gross margin of 90.0%, suggesting efficient cost management for its current products. However, the significant negative profit margin of -15050.2% and a small market capitalization of $5.18M highlight substantial ongoing operational losses and the need for significant future funding. Growth catalysts include successful clinical trial results and subsequent regulatory approvals for its pipeline products, which could unlock new market opportunities. Securing additional financing is also critical for sustaining operations and advancing its development efforts. The stock's Beta of 1.32 suggests higher volatility, and its listing on the OTC Other tier implies inherent risks related to liquidity and disclosure, necessitating careful investor scrutiny of future operational and financial developments.
Based on FMP financials and quantitative analysis
TLIS Key Highlights
Market Capitalization: $0.01 billion, indicating a micro-cap company operating in the specialized molecular diagnostics sector.
- Gross Margin: 90.0%, reflecting strong pricing power or efficient cost of goods sold for its current diagnostic offerings.
- Profit Margin: -15050.2%, highlighting significant operating losses relative to revenue, typical for a development-stage biotech firm.
- Beta: 1.32, suggesting that the stock's price tends to be more volatile than the broader market.
- Employee Count: 99 employees, indicating a relatively small, specialized workforce focused on research, development, and commercialization of diagnostic systems.
Who Are TLIS's Competitors?
TLIS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TLIS's Key Strengths?
Proprietary Talis One system technology for molecular diagnostics.
- Broad pipeline of diagnostic tests targeting respiratory, women's health, and STIs.
- Strategic focus on point-of-care testing, aligning with market demand for rapid results.
- High gross margin of 90.0% on current offerings.
What Are TLIS's Weaknesses?
Significant negative profit margin of -15050.2%, indicating substantial operational losses.
- Small market capitalization of $5.18M, suggesting limited financial scale.
- Operating on the OTC Other tier, implying higher risk and limited liquidity.
- Reliance on future regulatory approvals and securing additional funding for pipeline development and commercialization.
What Could Drive TLIS Stock Higher?
TLIS catalyst: Successful clinical trial results for pipeline products, such as the Talis One assay kits for respiratory infections, women's health, or STIs, demonstrating efficacy and safety.
- Receipt of key regulatory approvals (e.g., FDA Emergency Use Authorization or 510(k) clearance) for its Talis One assay kits, enabling broader commercialization.
- Securing additional significant funding rounds or strategic partnerships to support ongoing research and development, manufacturing, and commercial expansion.
- Continued development and refinement of the Talis One system, enhancing its capabilities and expanding its diagnostic menu.
What Are the Key Risks for TLIS?
Financial-distress signal — its Altman Z-Score of -12.28 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-63.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
- Significant negative profit margin of -15050.2%, indicating a high cash burn rate that necessitates continuous funding.
- Operating on the OTC Other tier, which presents inherent risks related to limited liquidity, price volatility, and reduced transparency for investors.
- Failure to achieve timely and successful regulatory approvals for its pipeline products, which could delay or prevent market entry.
- Inability to secure sufficient additional funding to sustain operations, advance its product pipeline, and scale commercial activities.
- Intense competition within the molecular diagnostics and point-of-care testing markets, potentially limiting market share and pricing power.
What Are the Growth Opportunities for TLIS?
- Expansion into Respiratory Panel Testing: Talis Biomedical is developing a Talis One assay kit for respiratory infections, including a panel test for influenza A, influenza B, and respiratory syncytial virus (RSV). The global respiratory diagnostics market is substantial, driven by seasonal outbreaks and the need for rapid differentiation of pathogens. By offering a multiplex test at the point of care, Talis can tap into a market seeking efficient and comprehensive solutions, potentially reducing misdiagnosis and improving patient management. This expansion could provide a significant revenue stream as the platform gains broader clinical acceptance, with a timeline dependent on successful clinical trials and regulatory approvals.
- Diversification into Women's Health Diagnostics: The company's pipeline includes Talis One assay kits targeting women's health infections. The women's health diagnostics market is a growing sector, fueled by increased awareness, routine screenings, and the need for accurate and timely diagnosis of conditions that can impact reproductive health and overall well-being. By offering point-of-care solutions in this area, Talis could address unmet needs for rapid, sensitive, and convenient testing, potentially improving patient access to care and treatment initiation. This represents a strategic move into a market with consistent demand and potential for sustained growth.
- Entry into Sexually Transmitted Infection (STI) Diagnostics: Talis Biomedical is developing Talis One assay kits for sexually transmitted infections. The global STI diagnostics market is driven by the high prevalence of STIs and the critical need for early and accurate detection to prevent transmission and complications. Point-of-care testing for STIs can significantly improve patient follow-up and treatment adherence compared to traditional lab-based methods. By providing rapid, accessible, and potentially discreet testing options, Talis could capture a share of this market, addressing a public health imperative with a convenient diagnostic solution.
- Leveraging Point-of-Care (POC) Market Growth: The overall market for point-of-care diagnostics is experiencing robust growth, driven by the demand for faster results, decentralized testing, and reduced healthcare costs. Talis Biomedical's core strategy aligns perfectly with this trend, as its Talis One system is designed specifically for POC applications. As healthcare systems increasingly adopt distributed testing models, Talis stands to benefit from the broader market shift towards immediate diagnostic insights in various settings, from clinics to urgent care centers. This macro trend provides a strong tailwind for the adoption of its platform and future assays.
- Platform Technology Expansion: The Talis One system itself represents a versatile molecular diagnostics platform capable of supporting a wide range of assays beyond its current pipeline. This inherent flexibility allows Talis Biomedical to develop and introduce new diagnostic tests for emerging pathogens or other disease areas without requiring a complete overhaul of its core technology. The ability to continuously expand its test menu on a single platform provides a long-term growth opportunity, enabling the company to adapt to evolving diagnostic needs and market demands, thereby extending the utility and commercial lifespan of its foundational technology.
What Threats Does TLIS Face?
- Intense competition from established diagnostic companies and other innovative biotech firms.
- Significant regulatory hurdles and potential delays in obtaining approvals for new products.
- Challenges in securing adequate funding to sustain operations and advance its extensive pipeline.
- Risk of technological obsolescence or the emergence of superior diagnostic technologies from competitors.
What Are TLIS's Competitive Advantages?
- Proprietary Talis One system technology, designed to address specific limitations in current point-of-care diagnostics.
- An expanding pipeline of diverse assay kits for multiple infectious diseases, including respiratory, women's health, and STIs.
- Focus on rapid, molecular point-of-care testing, which offers a competitive advantage over traditional lab-based methods.
- Potential for platform scalability, allowing for the development of new tests on the existing Talis One infrastructure.
What Does TLIS Do?
Talis Biomedical Corporation, established in 2013 and headquartered in Menlo Park, California, is a molecular diagnostics company dedicated to advancing point-of-care testing for infectious diseases. The company's core innovation is the Talis One system, a proprietary platform engineered to overcome existing limitations in rapid diagnostic technologies. This system is designed to deliver accurate and timely results, which is critical for effective disease management and public health. Currently, Talis Biomedical offers the Talis One COVID-19 Test System, specifically developed for the detection of SARS-CoV-2, the virus responsible for the ongoing global pandemic. This product represents a tangible application of their platform's capabilities in addressing immediate public health needs. Beyond its current COVID-19 offering, Talis Biomedical is actively developing a robust pipeline of Talis One assay kits. These kits are intended to broaden the system's diagnostic utility across several high-impact areas, including respiratory infections, infections related to women's health, and sexually transmitted infections (STIs). The respiratory infection pipeline notably includes a comprehensive panel test designed to identify multiple common pathogens, such as influenza A, influenza B, and respiratory syncytial virus (RSV). This strategic expansion aims to position the Talis One system as a versatile diagnostic tool capable of addressing a wide spectrum of infectious diseases at the point of care, thereby enhancing accessibility and speed of diagnosis in various clinical settings. With 99 employees, Talis Biomedical operates as a specialized entity within the medical devices sector, focusing its expertise on molecular diagnostics innovation.
What Products and Services Does TLIS Offer?
- Develops molecular diagnostic systems for infectious diseases.
- Focuses on creating point-of-care testing solutions.
- Offers the Talis One COVID-19 Test System for SARS-CoV-2 detection.
- Develops Talis One assay kits for various respiratory infections.
- Is creating diagnostic tests for women's health infections.
- Is developing assay kits for sexually transmitted infections (STIs).
- Pipeline includes a panel test for influenza A, influenza B, and respiratory syncytial virus (RSV).
- Headquartered in Menlo Park, California, established in 2013.
How Does TLIS Make Money?
- Researches, develops, and commercializes proprietary molecular diagnostic platforms and associated assay kits.
- Generates revenue through the sale of its Talis One system and specific diagnostic test cartridges.
- Aims to address limitations in existing point-of-care diagnostic technologies by offering rapid and accurate solutions.
- Focuses on expanding its product portfolio across multiple infectious disease categories, including respiratory, women's health, and STIs.
What Industry Does TLIS Operate In?
Talis Biomedical Corporation operates within the dynamic and rapidly evolving molecular diagnostics industry, specifically targeting the point-of-care (POC) testing segment. This segment is characterized by a growing demand for rapid, accurate, and decentralized diagnostic solutions, driven by the need for quicker clinical decisions and improved patient outcomes. The broader molecular diagnostics market is experiencing significant expansion, fueled by technological advancements, increasing prevalence of infectious diseases, and a shift towards personalized medicine. Talis Biomedical positions itself by focusing on addressing existing limitations in current POC technologies, aiming to differentiate its Talis One system through enhanced performance and versatility. The competitive landscape includes established diagnostic giants and numerous smaller, innovative biotech firms. Talis's strategy involves expanding its assay pipeline beyond COVID-19 into respiratory, women's health, and sexually transmitted infections, aligning with major market trends for comprehensive diagnostic panels and accessible testing.
Who Are TLIS's Key Customers?
- Healthcare providers and clinics requiring rapid, on-site infectious disease testing.
- Urgent care centers and emergency departments seeking immediate diagnostic results.
- Decentralized healthcare facilities and laboratories looking for efficient molecular testing solutions.
- Potentially, public health organizations and government agencies for broader disease surveillance.
Earnings Track Record
Talis Biomedical Corporation has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 296.4% below estimates on average.
Financial Health
Talis Biomedical Corporation's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.28 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Talis Biomedical Corporation stands at -63.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -65.5%, showing how much profit it generates from its asset base. A current ratio of 8.86 indicates the company holds enough short-term assets to cover its near-term obligations.
Talis Biomedical Corporation (TLIS) Valuation Context
Valued at $5.18M, TLIS is classified as a micro-cap stock. Relative to its peer group, TLIS's quantitative score of 51/100 is below the peer average of 65/100.
Company Profile
Talis Biomedical Corporation operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Menlo Park, US. The company is led by CEO Rebecca Markovich. TLIS has traded publicly since 2021.
TLIS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Talis Biomedical's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with many discussions highlighting the innovative aspects of their diagnostic technology.
- The company's recent partnerships and collaborations have generated excitement, positioning them well within the healthcare sector.
- Market perception is improving as analysts recognize the potential impact of Talis's products on patient care, amplifying interest among investors.
Bear Case
- Concerns over regulatory approvals remain a significant hurdle, creating uncertainty about the timeline for product launches.
- Recent discussions within the community reveal skepticism about the scalability of Talis's technology, which could hinder growth prospects.
- The competitive landscape in the biomedical field is fierce, with established players posing a threat to Talis's market entry.
- Market volatility has led to cautious sentiment, with some investors wary of the risks associated with emerging biotech firms like Talis.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2024 | $73,000 | -$13M | -$7.15 |
Based on FMP financials and quantitative analysis
TLIS Latest News
No recent news available for TLIS.
TLIS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TLIS.
Price Targets
Wall Street price target analysis for TLIS.
TLIS MoonshotScore
What does this score mean?
The MoonshotScore rates TLIS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Rebecca Markovich
CEO
Unknown
Track Record: Unknown
TLIS OTC Market Information
Talis Biomedical Corporation trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group. Unlike major exchanges like NYSE or NASDAQ, which have stringent listing requirements for financial health, corporate governance, and disclosure, the OTC Other tier has minimal to no public disclosure requirements. This tier is typically for companies that do not meet the standards for higher OTC tiers (like OTCQX or OTCQB) or major exchanges, often due to financial distress, limited operations, or non-compliance with reporting standards. This classification signals significantly higher risk for investors due to less available information and oversight.
- OTC Tier: OTC Other
- Limited public disclosure, making it difficult for investors to access comprehensive financial and operational information.
- Extremely low trading volume and wide bid-ask spreads, leading to significant liquidity risk and difficulty in executing trades.
- Increased susceptibility to price manipulation and volatility due to limited oversight and low trading activity.
- Difficulty in raising capital through traditional equity offerings due to the speculative nature and lack of investor confidence associated with the OTC Other tier.
- Higher potential for delisting or ceasing public quotation if the company fails to maintain even minimal operational or financial activity.
- Verify any available financial reports and disclosures, even if limited, to understand the company's financial health.
- Scrutinize the background and experience of management and board members, given the reduced oversight.
- Thoroughly research the company's business operations, product development status, and market potential independently.
- Assess the regulatory status of its products and pipeline, including any pending approvals or compliance issues.
- Investigate the company's current funding situation and its ability to secure additional capital for future operations.
- Understand the market for its products and the competitive landscape, considering the company's small scale.
- Evaluate any recent news, press releases, or corporate actions for insights into its ongoing viability.
- Established in 2013, indicating a foundational history in the industry.
- Headquartered in Menlo Park, US, a known hub for biotechnology and innovation.
- Specific product offerings, such as the Talis One COVID-19 Test System, demonstrate tangible development.
- Clear pipeline of diagnostic tests for various infectious diseases, including respiratory, women's health, and STIs.
- Maintains a workforce of 99 employees, suggesting ongoing operational activity and development efforts.
Common Questions About TLIS (Healthcare)
What does the AI Score mean for TLIS?
TLIS holds an AI Score of 51/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Talis Biomedical Corporation specializes in molecular diagnostics, developing the Talis One system for point-of-care infectious disease testing. The company currently offers a COVID-19 test and is …
What does Talis Biomedical Corporation do?
Talis Biomedical Corporation is a molecular diagnostics company focused on developing and commercializing its proprietary Talis One system for point-of-care infectious disease testing. The company's primary offering is the Talis One COVID-19 Test System, designed for rapid detection of SARS-CoV-2.
How does Talis Biomedical Corporation navigate regulatory approval processes?
As a medical device company operating in the molecular diagnostics space, Talis Biomedical Corporation's ability to bring its products to market is critically dependent on navigating stringent regulatory approval processes, primarily with agencies like the U.S. Food and Drug Administration (FDA).
What are the main risks for TLIS?
Talis Biomedical Corporation faces several significant risks that investors may want to evaluate. Financially, the company exhibits a substantial negative profit margin of -15050.2%, indicating a high rate of cash consumption relative to its revenue. This necessitates continuous and successful capital raises to fund its ongoing research, development, and potential commercialization efforts.
What are the key growth opportunities for TLIS in healthcare?
Talis Biomedical Corporation has several key growth opportunities within the healthcare sector, primarily driven by its focus on expanding the utility of its Talis One system. A significant opportunity lies in diversifying its product portfolio beyond COVID-19 testing into other high-demand areas, such as respiratory infection panels, women's health diagnostics, and sexually transmitted infection (STI) testing.
What are the key factors to evaluate for TLIS?
Talis Biomedical Corporation (TLIS) holds an AI score of 51/100 (moderate). Talis Biomedical Corporation is positioned in the molecular diagnostics market with its proprietary Talis One system, designed for rapid point-of-care infectious disease testing. Not financial advice.
How frequently does TLIS data refresh on this page?
TLIS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TLIS's recent stock price performance?
Talis Biomedical Corporation (TLIS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Talis One system technology for molecular diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TLIS overvalued or undervalued right now?
Talis Biomedical Corporation (TLIS) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited to provided source data.
- Specific details on CEO background and track record are not available in the provided sources, hence 'Unknown' is used.
- No specific competitor information or analyst ratings were provided in the source data, leading to an empty 'competitors' array and omission of an analyst FAQ.